Калькуляторы

Оценка инсулинорезистентности HOMA-IR

Сдаётся натощак вместе с глюкозой.

Примечание

Формула: HOMA-IR = (инсулин натощак [пмоль/л] × глюкоза натощак [ммоль/л]) / 135.

Единого общепринятого порога нет. В клинической практике и исследованиях в США часто используют значения 2,0–3,0. В NHANES для инсулинорезистентности применяют порог ≥2,5.

Учитывайте популяцию и контекст: у взрослых без диабета (NHANES III) медиана HOMA-IR — 2,2; у подростков с ожирением среднее — 4,9. Для азиатских популяций пороги метаболического синдрома обычно ниже (1,4–2,5).

Основа коррекции ранней инсулинорезистентности — модификация образа жизни. При недостаточном эффекте рассматривают фармакотерапию с учётом снижения массы тела и сердечно-сосудистых факторов риска.

СПИСОК ЛИТЕРАТУРЫ И БИБЛИОГРАФИЧЕСКИХ ССЫЛОК:

  1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.
  2. Lin SY, Li WC, Yang TA, et al. Optimal threshold of homeostasis model assessment of insulin resistance for defining metabolic syndrome in Chinese population aged 45 years or younger. Front Endocrinol (Lausanne). 2022;12. doi:10.3389/fendo.2021.746747
  3. Lee CH, Shih AZL, Woo YC, et al. Optimal cut-offs of homeostasis model assessment of insulin resistance (HOMA-IR) to identify dysglycemia and type 2 diabetes mellitus: a 15-year prospective study in Chinese. PLoS One. 2016;11(9). doi:10.1371/journal.pone.0163424
  4. Holzinger U, Kitzberger R, Fuhrmann V, Funk GC, Madl C, Ratheiser K. Correlation of calculated indices of insulin resistance (QUICKI and HOMA) with the euglycaemic hyperinsulinaemic clamp technique for assessing insulin resistance in critically ill patients. Eur J Anaesthesiol. 2007;24(11):966-970. doi:10.1017/S0265021507001111
  5. Sarafidis PA, Lasaridis AN, Nilsson PM, et al. Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. J Hum Hypertens. 2007;21(9):709-716. doi:10.1038/sj.jhh.1002201
  6. Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter JB, Supiano MA. Limitation of the homeostasis model assessment to predict insulin resistance and beta-cell dysfunction in older people. J Clin Endocrinol Metab. 2006;91(2):629-634. doi:10.1210/jc.2005-1803
  7. Bravata DM, Wells CK, Concato J, Kernan WN, Brass LM, Gulanski BI. Two measures of insulin sensitivity provided similar information in a U.S. population. J Clin Epidemiol. 2004;57(11):1214-1217. doi:10.1016/j.jclinepi.2004.05.001
  8. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J. 2001;48(1):81-86. doi:10.1507/endocrj.48.81
  9. Katsuki A, Sumida Y, Gabazza EC, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001;24(2):362-365. doi:10.2337/diacare.24.2.362
  10. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23(1):57-63. doi:10.2337/diacare.23.1.57
  11. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes. 1999;48(9):1779-1786. doi:10.2337/diabetes.48.9.1779
  12. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care. 1997;20(7):1087-1092. doi:10.2337/diacare.20.7.1087
  13. García-Hermoso A, López-Gil JF, Izquierdo M, Ramírez-Vélez R, Ezzatvar Y. Exercise and markers of insulin resistance in overweight and obese children and adolescents: a systematic review and network meta-analysis. JAMA Pediatr. 2023;177(12):1276-1284. doi:10.1001/jamapediatrics.2023.4038
  14. Parcha V, Heindl B, Kalra R, et al. Insulin resistance and cardiometabolic risk profile among nondiabetic American young adults: insights from NHANES. J Clin Endocrinol Metab. 2022;107(1):E25-E37. doi:10.1210/clinem/dgab645
  15. Matli B, Schulz A, Koeck T, et al. Distribution of HOMA-IR in a population-based cohort and proposal for reference intervals. Clin Chem Lab Med. 2021;59(11):1844-1851. doi:10.1515/cclm-2021-0643
  16. Yun KJ, Han K, Kim MK, et al. Insulin resistance distribution and cut-off value in Koreans from the 2008-2010 Korean National Health and Nutrition Examination Survey. PLoS One. 2016;11(4). doi:10.1371/journal.pone.0154593
  17. Otten J, Ahrén B, Olsson T. Surrogate measures of insulin sensitivity vs the hyperinsulinaemic-euglycaemic clamp: a meta-analysis. Diabetologia. 2014;57(9):1781-1788. doi:10.1007/s00125-014-3285-x
  18. Tohidi M, Ghasemi A, Hadaegh F, Derakhshan A, Chary A, Azizi F. Age- and sex-specific reference values for fasting serum insulin levels and insulin resistance/sensitivity indices in healthy Iranian adults: Tehran Lipid and Glucose Study. Clin Biochem. 2014;47(6):432-8. doi:10.1016/j.clinbiochem.2014.02.007
  19. Salgado AL, Carvalho L, Oliveira AC, Santos VN, Vieira JG, Parise ER. Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals. Arq Gastroenterol. 2010;47(2):165-9.
  20. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294(1). doi:10.1152/ajpendo.00645.2007
  21. Bermúdez-Pirela VJ, Cano C, Medina MT, et al. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA-IR) and β-cell function (HOMA-beta) without hyperinsulinemia in patients with type 2 diabetes mellitus. Am J Ther. 2007;14(2):194-202. doi:10.1097/01.pap.0000249909.54047.0e
  22. Vogeser M, König D, Frey I, Predel HG, Parhofer KG, Berg A. Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle changes in obese persons. Clin Biochem. 2007;40(13-14):964-968. doi:10.1016/j.clinbiochem.2007.05.009
  23. Lee JM, Okumura MJ, Davis MM, Herman WH, Gurney JG. Prevalence and determinants of insulin resistance among U.S. adolescents: a population-based study. Diabetes Care. 2006;29(11):2427-2432. doi:10.2337/dc06-0709
  24. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(3):1273-1276. doi:10.1210/jc.2003-031205
  25. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495. doi:10.2337/diacare.27.6.1487
Данная информация предназначена исключительно для специалистов в области здравоохранения с информационной целью.